However, there is variability in the detection rates of EGFR mutation in the blood compared with the standard methodology using tumour tissue, and the correlation of blood-derived EGFR mutation positivity with specific patient characteristics or clinical outcomes remains uncertain. Here, EGFR is linked to neoplasm.